- Home
- IAE vs CING Comparison
IAE vs CING Comparison
Compare IAE & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
IAE
Voya Asia Pacific High Dividend Equity Income Fund ING Asia Pacific High Dividend Equity Income Fund of Beneficial Interest
Current Price
Company Overview
Basic Information| Metric | IAE | CING |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.2M | 64.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | IAE | CING |
|---|---|---|
| Price | $8.39 | $5.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $34.50 |
| AVG Volume (30 Days) | 36.5K | ★ 437.2K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 10.21% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.40 | $3.20 |
| 52 Week High | $8.34 | $11.89 |
Technical Indicators
Market Signals| Indicator | IAE | CING |
|---|---|---|
| Relative Strength Index (RSI) | 67.32 | 43.71 |
| Support Level | $7.08 | $4.94 |
| Resistance Level | N/A | $6.79 |
| Average True Range (ATR) | 0.13 | 0.48 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 98.30 | 40.42 |
Price Performance
Historical ComparisonAbout IAE Voya Asia Pacific High Dividend Equity Income Fund ING Asia Pacific High Dividend Equity Income Fund of Beneficial Interest
Voya Asia Pacific High Dividend Equity Income Fund is a United States-based diversified, closed-end fund.The investment objective of the fund is to provide a total return through a combination of current income, capital gains, and capital appreciation. To achieve this objective, under normal market conditions, the fund invests in a portfolio of dividend-yielding equity securities of companies located in the Asia Pacific region.
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.